KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Expenses: 2020-2025

Historic Operating Expenses for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $177.4 million.

  • Recursion Pharmaceuticals' Operating Expenses rose 42.54% to $177.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.3 million, marking a year-over-year increase of 67.03%. This contributed to the annual value of $537.8 million for FY2024, which is 36.29% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Operating Expenses stood at $177.4 million, which was down 9.25% from $195.4 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Operating Expenses high stood at $206.1 million for Q1 2025, and its period low was $33.0 million during Q1 2021.
  • Its 3-year average for Operating Expenses is $137.4 million, with a median of $115.0 million in 2024.
  • Data for Recursion Pharmaceuticals' Operating Expenses shows a peak YoY surged of 138.73% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Operating Expenses stood at $67.5 million in 2021, then increased by 10.62% to $74.7 million in 2022, then spiked by 47.10% to $109.8 million in 2023, then surged by 71.47% to $188.3 million in 2024, then soared by 42.54% to $177.4 million in 2025.
  • Its Operating Expenses was $177.4 million in Q3 2025, compared to $195.4 million in Q2 2025 and $206.1 million in Q1 2025.